Literature DB >> 19773256

Anti-CD20 monoclonal antibodies: historical and future perspectives.

Sean H Lim1, Stephen A Beers, Ruth R French, Peter W M Johnson, Martin J Glennie, Mark S Cragg.   

Abstract

Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19773256      PMCID： PMC2805725          DOI： 10.3324/haematol.2008.001628

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  105 in total

1.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

2.  Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia.

Authors:  Abraham Klepfish; Amichai Schattner; Hussam Ghoti; Eliezer A Rachmilewitz
Journal:  Lancet Oncol       Date:  2007-04       Impact factor: 41.316

3.  The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cells.

Authors:  Jonna Eeva; Ulla Nuutinen; Antti Ropponen; Mikko Mättö; Mine Eray; Riikka Pellinen; Jarmo Wahlfors; Jukka Pelkonen
Journal:  Apoptosis       Date:  2009-05       Impact factor: 4.677

4.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

5.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

6.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

Authors:  S Alas; C Emmanouilides; B Bonavida
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

7.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Authors:  J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

8.  Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils.

Authors:  Mami Shibata-Koyama; Shigeru Iida; Hirofumi Misaka; Katsuhiro Mori; Keiichi Yano; Kenya Shitara; Mitsuo Satoh
Journal:  Exp Hematol       Date:  2009-03       Impact factor: 3.084

9.  Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.

Authors:  Claudia Stolz; Georg Hess; Patricia S Hähnel; Florian Grabellus; Sandra Hoffarth; Kurt W Schmid; Martin Schuler
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

10.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113
View more
  62 in total

1.  Raising hematology's European voice: the importance of calling yourself a hematologist.

Authors:  Thom Duyvené de Wit; Arndt Borkhardt; Christine Chomienne; Hartmut Döhner; Willem E Fibbe; Robin Foà; Anton Hagenbeek; Radek C Skoda; Carin R Smand; Ulrich Jäger
Journal:  Haematologica       Date:  2012-04       Impact factor: 9.941

2.  Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.

Authors:  Jorge Méndez-Navarro; Kathleen E Corey; Hui Zheng; Lydia L Barlow; Jae Young Jang; Wenyu Lin; Hong Zhao; Run-Xuan Shao; Steven L McAfee; Raymond T Chung
Journal:  Liver Int       Date:  2010-08-25       Impact factor: 5.828

Review 3.  Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.

Authors:  Sameer A Parikh; William G Wierda
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-06

Review 4.  Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.

Authors:  Ezogelin Oflazoglu; Laurent P Audoly
Journal:  MAbs       Date:  2010-01-30       Impact factor: 5.857

5.  Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients.

Authors:  Junji Tanaka; Norina Tanaka; Yan-Hua Wang; Kenjiro Mitsuhashi; Michiko Ryuzaki; Yuki Iizuka; Aya Watanabe; Midori Ishiyama; Akihito Shinohara; Hiroshi Kazama; Shotaro Hagiwara; Kentaro Yoshinaga; Yumi Kougen; Hirohito Kobayashi; Hitoshi Kanno; Masayuki Shiseki
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

Review 6.  Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells.

Authors:  Fabrizio Marcucci; Matteo Bellone; Cristiano Rumio; Angelo Corti
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

7.  Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

Authors:  Christian Klein; Alfred Lammens; Wolfgang Schäfer; Guy Georges; Manfred Schwaiger; Ekkehard Mössner; Karl-Peter Hopfner; Pablo Umaña; Gerhard Niederfellner
Journal:  MAbs       Date:  2012-12-04       Impact factor: 5.857

Review 8.  Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer.

Authors:  Myron Arlen; Philip Arlen; Gene Coppa; Jim Crawford; XuePing Wang; Olga Saric; Alex Dubeykovskiy; Ernesto Molmenti
Journal:  World J Gastrointest Oncol       Date:  2014-06-15

9.  18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.

Authors:  Kirstin A Zettlitz; Richard Tavaré; Wen-Ting K Tsai; Reiko E Yamada; Noel S Ha; Jeffrey Collins; R Michael van Dam; John M Timmerman; Anna M Wu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11-19       Impact factor: 9.236

10.  A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells.

Authors:  Hideaki Mabashi-Asazuma; Chu-Wei Kuo; Kay-Hooi Khoo; Donald L Jarvis
Journal:  Glycobiology       Date:  2013-12-20       Impact factor: 4.313
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.